AU2021261060A1 - Compositions and methods for treatment of Acute Respiratory Distress Syndrome - Google Patents

Compositions and methods for treatment of Acute Respiratory Distress Syndrome Download PDF

Info

Publication number
AU2021261060A1
AU2021261060A1 AU2021261060A AU2021261060A AU2021261060A1 AU 2021261060 A1 AU2021261060 A1 AU 2021261060A1 AU 2021261060 A AU2021261060 A AU 2021261060A AU 2021261060 A AU2021261060 A AU 2021261060A AU 2021261060 A1 AU2021261060 A1 AU 2021261060A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
antibody
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021261060A
Other languages
English (en)
Inventor
Michael John BROOKS
Blair Richard George GORDON
Pardeep Nijhawan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Edesa Biotech Research Inc
Original Assignee
Edesa Biotech Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edesa Biotech Research Inc filed Critical Edesa Biotech Research Inc
Publication of AU2021261060A1 publication Critical patent/AU2021261060A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2021261060A 2020-04-20 2021-04-20 Compositions and methods for treatment of Acute Respiratory Distress Syndrome Pending AU2021261060A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063012786P 2020-04-20 2020-04-20
US202063012783P 2020-04-20 2020-04-20
US63/012,783 2020-04-20
US63/012,786 2020-04-20
US202063081662P 2020-09-22 2020-09-22
US63/081,662 2020-09-22
PCT/CA2021/050544 WO2021212222A1 (en) 2020-04-20 2021-04-20 Compositions and methods for treatment of acute respiratory distress syndrome

Publications (1)

Publication Number Publication Date
AU2021261060A1 true AU2021261060A1 (en) 2022-11-17

Family

ID=78270861

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021261060A Pending AU2021261060A1 (en) 2020-04-20 2021-04-20 Compositions and methods for treatment of Acute Respiratory Distress Syndrome

Country Status (8)

Country Link
US (1) US20230192881A1 (https=)
EP (1) EP4138912A4 (https=)
JP (1) JP2023523096A (https=)
CN (1) CN115697410A (https=)
AU (1) AU2021261060A1 (https=)
CA (1) CA3174429A1 (https=)
IL (1) IL297363A (https=)
WO (1) WO2021212222A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020149518A1 (ko) * 2019-01-14 2020-07-23 주식회사 에이아이인사이트 안저영상 자동판독을 위한 딥러닝 아키텍처 시스템 및 딥러닝 아키텍쳐 시스템을 이용한 안저영상 자동판독 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674884B2 (en) * 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
US7312320B2 (en) * 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
JP2010526868A (ja) * 2007-05-14 2010-08-05 ノビミューン エスアー 改変されたエフェクター機能を有するＦｃ受容体結合ポリペプチド
US8734790B2 (en) * 2011-01-10 2014-05-27 Novimmune Sa Anti-TLR4 antibodies and methods of use thereof
HUE037613T2 (hu) * 2012-03-29 2018-09-28 Novimmune Sa Anti-TLR4 antitestek és azok felhasználása
WO2015059168A1 (en) * 2013-10-22 2015-04-30 Novimmune S.A. Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers
US20170038381A1 (en) * 2015-08-06 2017-02-09 Novimmune Sa Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders
CA3037961A1 (en) * 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody

Also Published As

Publication number Publication date
JP2023523096A (ja) 2023-06-01
EP4138912A4 (en) 2024-08-07
CA3174429A1 (en) 2021-10-28
WO2021212222A1 (en) 2021-10-28
CN115697410A (zh) 2023-02-03
IL297363A (en) 2022-12-01
EP4138912A1 (en) 2023-03-01
US20230192881A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
US11866503B2 (en) Methods for treating inflammatory conditions of the airway or lungs by administering antagonist monoclonal antibodies to interleukin-33 and interleukin-4 receptor
JP6858182B2 (ja) インターロイキン３３（ｉｌ−３３）媒介疾患に関するバイオマーカーおよびその使用
CN102046199A (zh) 使用抗mif抗体的治疗方法
IL239965A (en) Use of a protein-specific antigen-binding antagonist, alpha 4 beta 7 heterodimer for the preparation of a particular drug for treating a patient with an abnormal passage of cells expressing alpha 4 beta 7 to tissues containing expressing cells!
HK1244229A1 (zh) 治疗CROHN病的整联蛋白β7拮抗剂和方法
KR20210114964A (ko) 화농성 한선염 치료에 사용하기 위한 항-cd40 항체
AU2021213403B2 (en) Anti-αvβ8 integrin antibodies for use in treating kidney disease
KR20200143718A (ko) 이식편 거부반응 예방에 사용하기 위한 항-cd40 항체
WO2021211940A1 (en) Methods for treating a complement mediated disorder caused by viruses
CA2856866C (en) Administration of alpha4beta7 hetero-dimer-specific antibody
US10689441B2 (en) Anti—TLR4 antibodies and methods of use thereof
US20230192881A1 (en) Compositions and methods for treatment of acute respiratory distress syndrome
US20170038381A1 (en) Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders
US12583929B2 (en) Method of treating acute respiratory distress syndrome
WO2025238052A1 (en) Depletion of plasmacytoid dendritic cells for the treatment of respiratory viral infections
AU2016208453A1 (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
HK40056920A (en) Integrin beta7 antagonists and methods of treating crohn's disease
EA051460B1 (ru) Способы лечения воспалительных состояний
EA043630B1 (ru) Способы лечения воспалительных состояний